Another License Out!East China Pharmaceutical Liculucan peptide is as soon as possible

On June 23, East China Pharmaceutical (SZ.000963) announced that it would reach a strategic cooperation with GulfpharmaceuticalInDustriespjsc (Julphar)), a well -known enterprise in the Middle East. Symptoms are in the development, production and commercialization of 17 countries such as the UAE, Saudi Arabia, Egypt, Kuwait, Oman, Balin, etc. in 17 countries in the Middle East and North Africa regions. According to the agreement, East China Pharmaceutical will receive authorized down payment, development and registration milestones, and net sales sharing of agreed proportion.

East China Pharmaceutical said that after the completion of this transaction, Leraru peptide injection will become the second overseas authorized product after TTP273, marking the company's diabetes field strength and research and development innovation capabilities internationally recognized again. The important milestone of R & D and innovation is expected to lay a solid foundation for future expansion of overseas markets.

East China Pharmaceutical Licula Peptide injection (diabetes indication) is the first domestic drug to submit a listing application. At present, drug registration and verification have been completed. It is expected to be approved to be listed in China by the end of 2022.

It is worth noting that the weight loss indication of East China Pharmaceutical Licula Peptide injection liquid has also completed the domestic III clinical research. It is expected to submit a listing application at the end of June this year. In the field of weight loss indications, there are currently no GLP-1 inhibitors in China, including the original drugs, and the application for listing. East China Pharmaceutical is expected to get the top spot.

The faucet of the hypoglycemic medicine "goes to the sea again" again

According to a report from the International Diabetes Alliance (IDF) in 2021, the prevalence of adult diabetes in the Middle East and North Africa (Mena) region is the highest in the world, with 46 million, accounting for 12.2%. In 2045, one of each of them is expected to have diabetes; adult diabetic (20-79 years old) market size is about $ 7.6 billion. Public data shows that among the top 50 in the world, the Middle East and North Africa occupy 18 of the top 50 countries. Among them, Kuwait has the highest obesity rate (37.90%), which is the 11th largest obesity country in the world, ranking before the United States.

Jime, East China Pharmaceutical's authorized cooperation with the outside world, is one of the largest pharmaceuticals in the Middle East and Africa and one of the world's leading insulin producers. Emperor's 12 international -certified manufacturing factories.

In this regard, Lu Liang, chairman of East China Pharmaceutical, said: Julphar and East China Medicine are deeply cultivated in the diabetes field with large bases and wide market demand. East China Pharmaceutical is honored to work with JulPhar to give full play to each other's advantages to achieve the successful listing of Leraru peptide injections in the Middle East and North Africa regions, bringing well -being in more patients around the world.

As a leading domestic diabetes, East China Pharmaceutical's research on products and commercialization has been internationally recognized. In September 2021, East China Pharmaceutical's successful global Innovation GLP-1 oral small molecular product TTP273 will be authorized to South Korea, with a total amount of up to 39 million US dollars, realizing the company's first Licenseout transaction. Subsequently, in October 2021, East China Pharmaceutical and Japan Takeda Pharmaceutical reached a strategic cooperation on the commercial rights and interests of China's regional regional region on benzoic acid, which fully reflected the commercialization of East China Pharmaceutical in the domestic diabetic market. According to the Minutes of East China Medicine on April 28, the Minutes of the Investor Activities Discovery, since this year, Nicinna ® (Agleine tablets) in the marketing process is very good, showing a good growth trend. As the subsequent epidemic improves, Nihuna® is expected to further go to the market to complete the established sales target this year.

East China Pharmaceutical Litu Peptide is expected to be approved for reducing sugar and weight loss indications during the year.

The cooperative product Licula peptide injection is human pancreatic hypotonin-1 (GLP-1) receptor agonist. The original drug was developed by Nuo and Nord, which is currently the highest cumulative GLP-1 in the world. Receptor agonist. In 2021, the global sales of Licolatic peptides were about 2.286 billion US dollars, and China's sales were about 1.494 billion yuan, an increase of 45%year -on -year. At present, the original research drug products in China are selling, and the domestic alternative space is broad.

GLP-1 drugs represented by Leralugin show a significant treatment effect in weight loss, and the market size has grown rapidly. In China, there are no GLP-1 drugs to be approved to reduce weight. East China Pharmaceutical Leraro Peptide injection is currently the fastest research and development. It has completed the domestic III phase of clinical research. It is expected to be submitted to the market at the end of June this year. GLP-1 weight loss product approved for listing.

Xingye Securities pointed out that the current Leralugin peptide developed by East China Pharmaceuticals is in the first echelon among domestic manufacturers. It is expected that after the two indications are approved, it is expected to rely on the sales advantages accumulated by East China Pharmaceutical in the field of diabetes. Performance growth.

From the perspective of the number and type of product pipeline, East China Pharmaceutical Commercialization and Heroglusted Pharmaceuticals have reached more than 20 models. Regardless of the number of products from the number of product reserves and target coverage areas, the average industry is at the forefront of the industry, and the layout of the product pipeline has reached the international advanced level, and has a strong first -mover advantage and comprehensive strength. East China Pharmaceutical ranked eighth among the TOP10 manufacturers in public hospitals in key cities in 2020, ranking first in local enterprises. Picture source: East China Medicine

Caitong Securities pointed out that the diabetes market is a traditional area of ​​traditional advantages in East China Pharmaceutical's fine cultivation. It has good brand effects, channel advantages, and one of the best sales capabilities in domestic pharmaceutical companies. East China Pharmaceutical has been deeply cultivating the diabetes market. The product pipelines not only have a complete type of drugs, but also the quality of the pipelines are obvious to all. The layout of the products is a heavy potential product with good competitive patterns and broad market space.

From Licensein's innovative products to reverse Licenseout to the sea, in terms of consolidating the advantages of the diabetic market, East China Pharmaceutical has been continuously cultivating in this field to consolidate the position of its industry leaders. The Licenseout of this product once again proved the market's powerful commercial cooperation capabilities to East China.

This article is the content of Yaozhi.com reprinting. The copyright of pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved, please leave a message with this website. We will delete the content as soon as possible.

- END -